MX2023010491A - Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis. - Google Patents
Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis.Info
- Publication number
- MX2023010491A MX2023010491A MX2023010491A MX2023010491A MX2023010491A MX 2023010491 A MX2023010491 A MX 2023010491A MX 2023010491 A MX2023010491 A MX 2023010491A MX 2023010491 A MX2023010491 A MX 2023010491A MX 2023010491 A MX2023010491 A MX 2023010491A
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- myasthenia gravis
- satralizumab
- Prior art date
Links
- 206010028417 myasthenia gravis Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940060041 satralizumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente descripción proporciona composiciones farmacéuticas para tratar o prevenir la miastenia gravis que comprenden satralizumab como ingrediente activo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021040206 | 2021-03-12 | ||
PCT/JP2022/010791 WO2022191306A1 (ja) | 2021-03-12 | 2022-03-11 | 重症筋無力症の治療または予防用の医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023010491A true MX2023010491A (es) | 2023-09-18 |
Family
ID=83228157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023010491A MX2023010491A (es) | 2021-03-12 | 2022-03-11 | Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240158518A1 (es) |
EP (1) | EP4306127A1 (es) |
JP (1) | JPWO2022191306A1 (es) |
KR (1) | KR20230156368A (es) |
CN (1) | CN117320749A (es) |
AU (1) | AU2022232856A1 (es) |
CA (1) | CA3211328A1 (es) |
IL (1) | IL305793A (es) |
MX (1) | MX2023010491A (es) |
TW (1) | TW202302143A (es) |
WO (1) | WO2022191306A1 (es) |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
CA1341152C (en) | 1988-01-22 | 2000-12-12 | Tadamitsu Kishimoto | Receptor protein for human b cell stimulatory factor-2 |
JPH03155795A (ja) | 1989-11-13 | 1991-07-03 | Chuzo Kishimoto | マウス・インターロイキン―6レセプター蛋白質 |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
RU2139351C1 (ru) | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69333823T2 (de) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
EP0817794A1 (en) | 1995-03-31 | 1998-01-14 | Jakob Bohr | Method for protein folding |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO2005028514A1 (en) | 2003-09-22 | 2005-03-31 | Biovation Gmbh & Co. Kg. | Use of a compound for reducing the biological effectiveness of il-6 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
RU2524152C2 (ru) | 2009-03-19 | 2014-07-27 | Чугаи Сейяку Кабусики Кайся | Средство для лечения ревматоидного артрита |
SG10201703707YA (en) | 2009-03-19 | 2017-06-29 | Chugai Pharmaceutical Co Ltd | Pharmaceutical formulation containing improved antibody molecules |
TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
KR20180095740A (ko) * | 2015-02-27 | 2018-08-27 | 추가이 세이야쿠 가부시키가이샤 | Il-6 관련 질환 치료용 조성물 |
-
2022
- 2022-03-11 JP JP2023505649A patent/JPWO2022191306A1/ja active Pending
- 2022-03-11 AU AU2022232856A patent/AU2022232856A1/en active Pending
- 2022-03-11 CA CA3211328A patent/CA3211328A1/en active Pending
- 2022-03-11 US US18/280,970 patent/US20240158518A1/en active Pending
- 2022-03-11 CN CN202280030321.9A patent/CN117320749A/zh active Pending
- 2022-03-11 TW TW111108920A patent/TW202302143A/zh unknown
- 2022-03-11 MX MX2023010491A patent/MX2023010491A/es unknown
- 2022-03-11 IL IL305793A patent/IL305793A/en unknown
- 2022-03-11 WO PCT/JP2022/010791 patent/WO2022191306A1/ja active Application Filing
- 2022-03-11 KR KR1020237033964A patent/KR20230156368A/ko unknown
- 2022-03-11 EP EP22767260.7A patent/EP4306127A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4306127A1 (en) | 2024-01-17 |
JPWO2022191306A1 (es) | 2022-09-15 |
KR20230156368A (ko) | 2023-11-14 |
TW202302143A (zh) | 2023-01-16 |
US20240158518A1 (en) | 2024-05-16 |
WO2022191306A1 (ja) | 2022-09-15 |
AU2022232856A1 (en) | 2023-10-26 |
CA3211328A1 (en) | 2022-09-15 |
CN117320749A (zh) | 2023-12-29 |
IL305793A (en) | 2023-11-01 |
AU2022232856A9 (en) | 2023-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ763551A (en) | Compounds useful for inhibiting cdk7 | |
SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
SG11201810704WA (en) | Sulfonamide compound or salt thereof | |
MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
MX2023005574A (es) | Analogos novedosos de carbanucleosidos sustituidos de sistema anular monociclico y biciclico para su uso como inhibidores de prmt5. | |
PH12020550683A1 (en) | Novel bradykinin b2 receptor antagonists | |
PH12020551486A1 (en) | Cyclopentane-based modulators of sting (stimulator of interferon genes) | |
EP4397309A3 (en) | Bicyclic ketone compounds and methods of use thereof | |
MX2021004474A (es) | Compuestos que contienen deuterio. | |
EP3909597A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING AN OLIGOPEPTIDE AS ACTIVE INSTRUMENT | |
WO2018039077A8 (en) | Therapeutic compounds | |
ZA202204442B (en) | Salt forms of a complement component c5a receptor | |
PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
MX2019008338A (es) | Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco. | |
EP4234021A3 (en) | Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy | |
AU2018246257A8 (en) | Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol | |
EP4286007A3 (en) | Pharmaceutical formulation | |
MX2022008487A (es) | Degradadores de smarca2-vhl. | |
MX2023002482A (es) | Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
PH12019502261A1 (en) | Therapeutic or prophylactic agent for peripheral neuropathies | |
MX2023010491A (es) | Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis. | |
WO2018102256A8 (en) | Pyrrolidinone compounds | |
MX2022002684A (es) | Metodo de tratamiento o prevencion de la enfermedad renal cronica. | |
PH12020500233A1 (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
WO2019070709A8 (en) | Compounds for treating or preventing flavivirus infections |